Lumos Diagnostics Holdings Ltd (ASX: LDX) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Lumos Diagnostics Holdings Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Lumos Diagnostics Holdings Ltd (ASX: LDX)
Latest News
Healthcare Shares
3 ASX healthcare shares rocketing 20% to 100% today
Healthcare Shares
Lumos Diagnostics share price rockets 1,036% in 2 days on FDA news
Ask a Fund Manager
Expert reveals one IPO he's absolutely pumped about. When will it hit the ASX?
Ask a Fund Manager
2 small-cap ASX shares to handsomely reward patient investors
Coronavirus News
Why are ASX COVID test shares climbing today?
Healthcare Shares
The Lumos Diagnostics (ASX:LDX) share price is soaring another 8% today. Here's why
Healthcare Shares
Why the Lumos Diagnostics (ASX:LDX) share price is up 15% today
Share Gainers
AnteoTech (ASX:ADO) share price gains 42% in a week amid RAT race
Healthcare Shares
Lumos Diagnostics (ASX:LDX) share price climbs amid RAT mania
Share Gainers
Lumos Diagnostics (ASX:LDX) share price up 9% on evaluation update
IPOs
Lumos Diagnostics (ASX:LDX) share price adds 9% on IPO, raising $63m
LDX ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Lumos Diagnostics Holdings Ltd
Lumos Diagnostics Holdings Ltd is engaged in the development, manufacture and distribution of point-of-care diagnostic (POC) tests and associated readers for analysis of POC diagnostic tests. It also directly develops, manufactures and commercializes proprietary, Lumos-branded POC tests that target infectious and inflammatory diseases. It generates maximum revenue from the commercial services and solutions relating to POC diagnostic tests.
LDX Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
19 Apr 2024 | $0.06 | $0.00 | 0.00% | 1,906,630 | $0.06 | $0.06 | $0.06 |
18 Apr 2024 | $0.06 | $0.00 | 0.00% | 2,617,829 | $0.06 | $0.06 | $0.06 |
17 Apr 2024 | $0.06 | $0.00 | 0.00% | 624,905 | $0.06 | $0.06 | $0.06 |
16 Apr 2024 | $0.06 | $0.00 | 0.00% | 2,560,222 | $0.06 | $0.06 | $0.06 |
15 Apr 2024 | $0.06 | $0.00 | 0.00% | 1,790,223 | $0.06 | $0.06 | $0.06 |
12 Apr 2024 | $0.06 | $0.00 | 0.00% | 922,102 | $0.06 | $0.07 | $0.06 |
11 Apr 2024 | $0.07 | $0.00 | 0.00% | 1,704,967 | $0.07 | $0.07 | $0.06 |
10 Apr 2024 | $0.07 | $0.00 | 0.00% | 1,193,050 | $0.07 | $0.07 | $0.07 |
09 Apr 2024 | $0.07 | $0.00 | 0.00% | 1,609,239 | $0.06 | $0.07 | $0.06 |
08 Apr 2024 | $0.06 | $0.00 | 0.00% | 1,679,182 | $0.07 | $0.07 | $0.06 |
05 Apr 2024 | $0.07 | $0.00 | 0.00% | 3,087,693 | $0.06 | $0.07 | $0.06 |
04 Apr 2024 | $0.06 | $0.00 | 0.00% | 3,588,210 | $0.06 | $0.06 | $0.06 |
03 Apr 2024 | $0.06 | $0.00 | 0.00% | 2,339,752 | $0.06 | $0.06 | $0.06 |
02 Apr 2024 | $0.06 | $0.00 | 0.00% | 947,885 | $0.06 | $0.06 | $0.06 |
28 Mar 2024 | $0.06 | $0.00 | 0.00% | 1,755,276 | $0.06 | $0.06 | $0.06 |
27 Mar 2024 | $0.06 | $0.00 | 0.00% | 2,779,210 | $0.06 | $0.06 | $0.06 |
26 Mar 2024 | $0.06 | $0.00 | 0.00% | 6,380,978 | $0.06 | $0.06 | $0.06 |
25 Mar 2024 | $0.06 | $0.00 | 0.00% | 4,574,325 | $0.06 | $0.06 | $0.06 |
22 Mar 2024 | $0.06 | $0.00 | 0.00% | 2,207,255 | $0.06 | $0.07 | $0.06 |
21 Mar 2024 | $0.07 | $0.00 | 0.00% | 1,298,588 | $0.07 | $0.07 | $0.06 |
20 Mar 2024 | $0.07 | $0.00 | 0.00% | 324,869 | $0.07 | $0.07 | $0.07 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
18 Oct 2023 | Doug Ward | Buy | 250,000 | $21,645 |
On-market trade.
|
03 Aug 2023 | Bronwyn Le Grice | Issued | 71,428 | $5,000 |
Participation in share purchase plan.
|
03 Aug 2023 | Catherine Robson | Issued | 428,571 | $30,000 |
Participation in share purchase plan.
|
03 Aug 2023 | Samuel Lanyon | Issued | 285,714 | $20,000 |
Participation in share purchase plan.
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Ms Bronwyn Joyce Le Grice | Non-Executive Director | Nov 2020 |
Ms Le Grice has more than 18 years of executive experience in the health technology sector spanning commercialization, venture capital, corporate development, capital raising and industry advocacy. Formerly an Investment Director with leading healthcare investment firm, BioScience Managers, Ms. Le Grice managed over $65M of private and public equity capital raisings and was actively involved in over $30M of portfolio investments. In 2017, she founded ANDHealth, Australia's only dedicated digital health accelerator and commercialization support organization which has led to significant growth within Australia's nascent digital health sector. Ms. Le Grice holds a number of health, technology and innovation advisory roles both in Australia and internationally, and is a Director of ANDHealth Pty Ltd. He is Chair of the Disclosure Committee and risk comittee
|
Ms Catherine Robson | Non-Executive Director | Dec 2020 |
Ms Robson has more than 20 years of experience in management, finance and investment. Ms. Robson currently chairs the Board of fully owned subsidiary Equity Trustees Superannuation Limited. Ms. Robson's other Board appointments include serving as a Non-Executive Director for Australia's largest customer owned bank, Newcastle Greater Mutual Group, where she chairs the Audit Committee. She is chairman of Risk Committee.
|
Ms Lawrence Mehren | Non-Executive Deputy ChairmanNon-Executive Director | Dec 2020 |
Mr Mehren served as President and Chief Executive Officer as well as a Director of Accelerate Diagnostics from 2012 to 2020. During his tenure, the company developed and launched its groundbreaking Accelerate Pheno instrument. Prior to this, Mr. Mehren was the Head of Global Business for Ventana Medical Systems and Roche Tissue Diagnostics managing its four business units. He also held various global leadership positions with Ventana including Senior Vice President of Emerging Businesses and Chief Financial Officer. Mr. Mehren was also Managing Director, Partner and Head of P&M Corporate Finance's life sciences practice
|
Mr Samuel Ross Garland Lanyon | Non-Executive ChairmanNon-Executive Director | Jun 2022 |
Mr Lanyon has more than 25 years of experience in strategy, sales and operations with a track record in the global commercialization of technology rich healthcare products. Mr. Lanyon currently serves as Executive Director and co-founder of Planet Innovation and a Non-Executive Director of Paragon Funds Management. He also serves as a Non-Executive Director of Visus Therapeutics, a clinical-stage company focused on developing innovation medicines to improve vision. Previously, Mr. Lanyon held international executive roles with Leica Microsystems, part of Danaher Corporation. He is a member of Member of the Disclosure Committee and risk committee.
|
Mr Doug Ward | Chief Executive OfficerManaging Director | Jun 2022 |
Mr Ward has 30 years experience as an executive in the diagnotics and healthcare industries. He joined from his previous role at the leading US womens healthcare company, Hologic. Prior to this, Doug was CEO of PDGX, a genomics in vitro diagnostics company that was acquired by LabCorp in 2022.
|
Ms Melanie Jaye Leydin | Chief Financial OfficerCompany Secretary |
-
|
|
Ms Tracy Weimar | Company Secretary |
-
|
|
Barrie Lambert | Chief Financial Officer |
-
|
|
Melanie Jaye Leydin | Chief Financial OfficerCompany Secretary |
-
|
|
Tracy Weimar | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
Planet Innovation Holdings Limited | 68,021,060 | 21.98% |
National Nominees Limited | 59,260,190 | 19.15% |
GZ Family Holdings Pty Ltd (Gz Family A/C) | 21,930,614 | 7.09% |
J P Morgan Nominees Australia Pty Limited | 18,765,171 | 6.06% |
Hsbc Custody Nominees (Australia) Limited | 14,161,707 | 4.58% |
Palm Beach Nominees Pty Limited | 9,169,876 | 2.96% |
H&G Investment Management Ltd (H&G Vail Lane Fund A/C) | 9,000,000 | 2.91% |
Hgl Investments Pty Ltd | 6,000,000 | 1.94% |
Comsec Nominees Pty Limited | 5,827,821 | 1.88% |
Mr James Stirling Whyte | 5,000,000 | 1.62% |
Bowvale Investments Pty Limited (Bowvale Investments S/F A/C) | 4,312,095 | 1.39% |
Paranji Super Fund Pty Ltd (Paranji Superfund A/C) | 4,000,000 | 1.29% |
Lind Global Fund Ii Lp | 3,982,979 | 1.29% |
Mr Kah Choon Wai | 3,500,000 | 1.13% |
Morsec Nominees Pty Ltd (Accumulation Account) | 2,897,241 | 0.94% |
Pineleaf Pty Limited (Smithers Super Fund A/C) | 2,782,792 | 0.90% |
Warbont Nominees Pty Ltd (Unpaid Entrepot A/C) | 2,757,355 | 0.89% |
Netshare Nominees Pty Ltd | 2,656,571 | 0.86% |
Third Party Nominees Pty Ltd (Accumulation A/C) | 2,494,084 | 0.81% |
Oceanview Victoria Pty Ltd (Oceanview Family A/C) | 2,000,000 | 0.65% |